Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Taiwan
/
Pharmaceuticals & Biotech
/
Lotus Pharmaceutical
1795
Lotus Pharmaceutical
Trade And Regulation Will Shrink Margins Yet Southeast Asia Aids
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
03 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
NT$250.00
22.4% undervalued
intrinsic discount
10 Aug
NT$194.00
Loading
1Y
-31.1%
7D
-3.2%
Author's Valuation
NT$250.0
22.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
NT$250.0
22.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-307m
22b
2014
2017
2020
2023
2025
2026
2028
Revenue NT$22.0b
Earnings NT$4.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.73%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.17%
Calculation
NT$4.08b
Earnings '28
x
18.66x
PE Ratio '28
=
NT$76.19b
Market Cap '28
NT$76.19b
Market Cap '28
/
266.24m
No. shares '28
=
NT$286.18
Share Price '28
NT$286.18
Share Price '28
Discounted to 2025 @ 5.17% p.a.
=
NT$246.02
Fair Value '25
